Journal of NeuroVirology

, Volume 18, Issue 4, pp 247–255 | Cite as

Accelerated aging and human immunodeficiency virus infection: Emerging challenges of growing older in the era of successful antiretroviral therapy



HIV-infected patients are living longer as a result of potent antiretroviral therapy. Immuno-inflammatory phenomena implicated in the normal aging process, including immune senescence, depreciation of the adaptive immune system, and heightened systemic inflammation are also pathophysiologic sequelae of HIV infection, suggesting HIV infection can potentiate the biological mechanisms of aging. Aging HIV-infected patients manifest many comorbidities at earlier ages, and sometimes with more aggressive phenotypes compared to seronegative counterparts. In this review, we describe relevant biologic changes shared by normal aging and HIV infection and explore the growing spectrum of clinical manifestations associated with the accelerated aging phenotype in HIV-infected individuals.


HIV Aging Immune senescence Chronic inflammation Cardiovascular Frailty 


  1. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E (2009) Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 4:190–199PubMedCrossRefGoogle Scholar
  2. Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N (2008) Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS 22(12):941–945PubMedCrossRefGoogle Scholar
  3. Alexeyev MF, Ledoux SP, Wilson GL (2004) Mitochondrial DNA and aging. Clin Sci (Lond) 107:355–364CrossRefGoogle Scholar
  4. Ances BM, Vaida F, Yeh MJ, Liang CL, Buxton RB, Letendre S, McCutchan JA, Ellis RJ (2010) HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 201(3):336–340PubMedCrossRefGoogle Scholar
  5. Ancuta P, Kamat A, Kunstman KJ et al (2008) Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3:e2516PubMedCrossRefGoogle Scholar
  6. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111(6):529–538PubMedCrossRefGoogle Scholar
  7. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799PubMedCrossRefGoogle Scholar
  8. Antiretroviral Therapy Collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293–299CrossRefGoogle Scholar
  9. Antiretroviral Therapy Collaboration (2010) Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50:1387–1396CrossRefGoogle Scholar
  10. Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214:231–241PubMedCrossRefGoogle Scholar
  11. Avelino-Silva VI, Ho YL, Avelino-Silva TJ, Santos Sde S (2011) Aging and HIV infection. Ageing Res Rev 10:163–172PubMedCrossRefGoogle Scholar
  12. Baker JV, Henry WK, Neaton JD (2009) The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 4(3):176–182PubMedCrossRefGoogle Scholar
  13. Beach RS, Morgan R, Wilkie F, Mantero-Atienza E, Blaney N, Shor-Posner G, Lu Y, Eisdorfer C, Baum MK (1992) Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1-related cognitive changes. Arch Neurol 49(5):501–506PubMedCrossRefGoogle Scholar
  14. Becker JT, Lopez OL, Dew MA, Aizenstein HJ (2004) Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18(Suppl 1):S11–S18PubMedGoogle Scholar
  15. Becker JT, Kingsley L, Mullen J, Cohen B, Martin E, Miller EN, Ragin A, Sacktor N, Selnes OA, Visscher BR (2009) Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 73:1292–1299PubMedCrossRefGoogle Scholar
  16. Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, De Paoli P, Lleshi A, Izzi I, Torresin A, Di Gangi P, Pietrangelo A, Ferrari M, Bearz A, Berretta S, Nasti G, Di Benedetto F, Balestreri L, Tirelli U, Ventura P (2011) Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 16(9):1258–1269PubMedCrossRefGoogle Scholar
  17. Bestilny LJ, Gill MJ, Mody CH, Riabowol KT (2000) Accelerated replicative senescence of the peripheral immune system induced by HIV infection. AIDS 14:771–780PubMedCrossRefGoogle Scholar
  18. Borjabad A, Morgello S, Chao W, Kim SY, Brooks AI, Murray J, Potash MJ, Volsky DJ (2011) Significant effects of antiretroviral therapy on global gene expression in brain tissue of patients with HIV-associated neurocognitive disorders. PLoS Pathog 7(9):e1002213PubMedCrossRefGoogle Scholar
  19. Bortz WM (2002) A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med Sci 57:M283–M288PubMedCrossRefGoogle Scholar
  20. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12:1365–1371PubMedCrossRefGoogle Scholar
  21. Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17):2165–2174PubMedCrossRefGoogle Scholar
  22. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475PubMedCrossRefGoogle Scholar
  23. Byrd DA, Fellows RP, Morgello S, Franklin D, Heaton RK, Deutsch R, Atkinson JH, Clifford DB, Collier AC, Marra CM, Gelman B, McCutchan JA, Duarte NA, Simpson DM, McArthur J, Grant I (2011) Neurocognitive impact of substance use in HIV infection. JAIDS 58(2):154–162PubMedCrossRefGoogle Scholar
  24. Centers for Disease Control and Prevention (2008) HIV/AIDS Surveillance Report, 2006. Vol. 18Google Scholar
  25. Centers for Disease Control and Prevention (2011) HIV Surveillance Report: Diagnoses of HIV infection and AIDS in the United States and Dependent Areas, 2009. Available at Accessed on October 27, 2011
  26. Centers for Disease Control and Prevention (2011b) HIV Surveillance United States, 1981–2008. Morb Mortal Wkly Rep 60(21):689–693Google Scholar
  27. Chang L, Ernst T, Poland RE, Jenden DJ (1996) In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 58(22):2049–2056PubMedCrossRefGoogle Scholar
  28. Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, Kolson D, Schifitto G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G, Navia BA (2004) A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 23(4):1336–1347PubMedCrossRefGoogle Scholar
  29. Chang L, Andres M, Sadino J, Jiang CS, Nakama H, Miller E, Ernst T (2011) Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotrophy and premature brain aging. Neuroimage 58(4):1017–1027PubMedCrossRefGoogle Scholar
  30. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L (2009) Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer 8(4):215–219PubMedCrossRefGoogle Scholar
  31. Corral I, Quereda C, Moreno A, Pérez-Elías MJ, Dronda F, Casado JL, Muriel A, Masjuán J, Alonso-de-Leciñana M, Moreno S (2009) Cerebrovascular ischemic events in HIV-1 infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis 27(6):559–563PubMedCrossRefGoogle Scholar
  32. Corsonello A, Garasto S, Abbatecola AM, Rose G, Passarino G, Mazzei B, Pranno L, Guffanti EE, Bustacchini S, Lattanzio F (2010) Targeting inflammation to slow or delay functional decline: where are we? Biogerontology 11:603–614PubMedCrossRefGoogle Scholar
  33. Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, Weintrob A, Barthel RV, Fraser S, Agan BK (2010) Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 5(4):e10106PubMedCrossRefGoogle Scholar
  34. Cysique LA, Maruff P, Bain MP, Wright E, Brew BJ (2011) HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 23(1):83–89PubMedCrossRefGoogle Scholar
  35. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155PubMedCrossRefGoogle Scholar
  36. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB (2007) HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 62(11):1279–1286PubMedCrossRefGoogle Scholar
  37. Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, Jacobson LP (2009) Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 50(3):299–306PubMedCrossRefGoogle Scholar
  38. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB (2011) A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci 66(9):1030–1038PubMedCrossRefGoogle Scholar
  39. Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, Yoder C, Jones E, Chow C, Metcalf JA, Sidorov IA, Dimitrov DS, Polis MA, Kovacs JA (2006) Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 80:2665–2674PubMedCrossRefGoogle Scholar
  40. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL (2011) Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case–control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr 57(3):245–253PubMedCrossRefGoogle Scholar
  41. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP (2008) Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 47(4):542–553Google Scholar
  42. Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, Reilly CS, Beilman GJ, George ME, Douek DC, Haase AT, Schacker TW (2008) Collagen deposition limits immune reconstitution in the gut. J Infect Dis 198:456–464PubMedCrossRefGoogle Scholar
  43. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128:92–105PubMedCrossRefGoogle Scholar
  44. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Med Sci 56(3):M146–M156CrossRefGoogle Scholar
  45. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356(17):1723–1735PubMedCrossRefGoogle Scholar
  46. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, Kalinowska M, Luciano AA, Stevens W, Rodriguez B, Brenchley JM, Douek DC, Lederman MM (2010) Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115:161–167PubMedCrossRefGoogle Scholar
  47. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 292(2):191–201PubMedCrossRefGoogle Scholar
  48. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19(4):401–411CrossRefGoogle Scholar
  49. Gruver AL, Hudson LL, Sempowski GD (2007) Immunosenescence of ageing. J Pathol 211:144–156PubMedCrossRefGoogle Scholar
  50. Guaraldi G, Zona S, Alexopoulos N, Orlando G, Carli F, Ligabue G, Fiocchi F, Lattanzi A, Rossi R, Modena MG, Esposito R, Palella F, Raggi P (2009) Coronary aging in HIV-infected patients. Clin Infect Dis 49(11):1756–1762PubMedCrossRefGoogle Scholar
  51. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F (2011a) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53(11):1120–1126PubMedCrossRefGoogle Scholar
  52. Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Fiocchi F, Menozzi M, Rossi R, Modena MG, Raggi P (2011b) Human immunodeficiency virus infection is associated with accelerated atherosclerosis. J Antimicrob Chemother 66(8):1857–1860PubMedCrossRefGoogle Scholar
  53. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12(3):204–212PubMedCrossRefGoogle Scholar
  54. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25(5):625–633PubMedCrossRefGoogle Scholar
  55. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75(23):2087–2096PubMedCrossRefGoogle Scholar
  56. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3–16PubMedCrossRefGoogle Scholar
  57. Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH (2008) The role of the thymus in HIV infection: a 10 year perspective. AIDS 22:171–184PubMedCrossRefGoogle Scholar
  58. Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD (2007) Trends in perimortal conditions and mortality rates among HIV infected patients. AIDS 21:2093–2100PubMedCrossRefGoogle Scholar
  59. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, Waters DD (2004a) Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109(3):316–319PubMedCrossRefGoogle Scholar
  60. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD (2004b) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109(13):1603–1608PubMedCrossRefGoogle Scholar
  61. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187:1534–1543PubMedCrossRefGoogle Scholar
  62. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197(1):126–133PubMedCrossRefGoogle Scholar
  63. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG (2011) Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 203:1474–1483PubMedCrossRefGoogle Scholar
  64. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, Keller MJ (2008) Risk factors for decreased bone mineral density and effects of HIV on bone in the elderly. Osteoporos Int 19(7):913–918PubMedCrossRefGoogle Scholar
  65. Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW (2010) Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther 16:7–9Google Scholar
  66. Kalayjian RC, Landay A, Pollard RB, Taub DD, Gross BH, Francis IR, Sevin A, Pu M, Spritzler J, Chernoff M, Namkung A, Fox L, Martinez A, Waterman K, Fiscus SA, Sha B, Johnson D, Slater S, Rousseau F, Lederman MM (2003) Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 187:1924–1933PubMedCrossRefGoogle Scholar
  67. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, Xue X, Hunt P, Karim R, Hern DM, Hodis HN, Deeks SG (2010) T-cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 203:452–463CrossRefGoogle Scholar
  68. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, Reiss P, Wit F (2011) Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 52(12):1458–1465PubMedCrossRefGoogle Scholar
  69. Khanlou N, Moore DJ, Chana G, Cherner M, Lazzaretto D, Dawes S, Grant I, Masliah E, Everall IP (2009) Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol 15(2):131–138PubMedCrossRefGoogle Scholar
  70. Kirk GD, Merlo C, O' Driscoll P, Mehta SH, Galai N, Vlahov D, Samet J, Engels EA (2007) HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 45(1):103–110PubMedCrossRefGoogle Scholar
  71. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30(5):471–477PubMedCrossRefGoogle Scholar
  72. Kramer-Hämmerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R (2005) Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111(2):194–213PubMedCrossRefGoogle Scholar
  73. Kroger H, Laitinen K (1992) Bone mineral density measured by dual-energy X-ray absorptiometry in normal men. Eur J Clin Invest 22(7):454–460PubMedCrossRefGoogle Scholar
  74. Kwan TS, Padrines M, Theoleyre S, Heymann D, Fortun Y (2004) IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15(1):49–60CrossRefGoogle Scholar
  75. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Bingham A, Costagliola D (2010) Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 24(8):1228–1230PubMedCrossRefGoogle Scholar
  76. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N (2007) Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 146:87–95PubMedGoogle Scholar
  77. Maagaard A, Holberg-Petersen M, Løvgården G, Holm M, Pettersen FO, Kvale D (2008) Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. J Infect Dis 198:1474–1481PubMedCrossRefGoogle Scholar
  78. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA (2011) Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 14(2):468–473CrossRefGoogle Scholar
  79. Masiá M, Bernal E, Padilla S, Graells ML, Jarrín I, Almenar MV, Molina J, Hernández I, Gutiérrez F (2007) The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 195(1):167–171PubMedCrossRefGoogle Scholar
  80. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, Daar E, Cercek B (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163(4):457–460PubMedCrossRefGoogle Scholar
  81. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C (2011) Impact of late diagnosis and treatment on life-expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 343:d6016. doi:10.1136/bmj.d6016 PubMedCrossRefGoogle Scholar
  82. Myers JD (2009) Growing old with HIV: the AIDS epidemic and an aging population. JAAPA 22:20–24PubMedGoogle Scholar
  83. Naesens M (2011) Replicative senescence in kidney aging, renal disease, and renal transplantation. Discov Med 11:65–75PubMedGoogle Scholar
  84. Nath A, Geiger J (1998) Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 54:19–33PubMedCrossRefGoogle Scholar
  85. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201:1788–1795PubMedCrossRefGoogle Scholar
  86. Paradies G, Petrosillo G, Paradies V, Ruggiero FM (2011) Mitochondrial dysfunction in brain aging: role of oxidative stress and cardiolipin. Neurochem Int 58:447–457PubMedCrossRefGoogle Scholar
  87. Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD (2008) Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 13(2):177–187PubMedGoogle Scholar
  88. Rasmussen LD, Engsig FN, Christensen H, Gerstoft J, Kronborg G, Pedersen C, Obel N (2011) Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 25(13):1637–1646PubMedCrossRefGoogle Scholar
  89. Rickabaugh TM, Kilpatrick RD, Hultin LE, Hultin PM, Hausner MA, Sugar CA, Althoff KN, Margolick JB, Rinaldo CR, Detels R, Phair J, Effros RB, Jamieson BD (2011) The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. PLoS One 6:e16459PubMedCrossRefGoogle Scholar
  90. Rodier F, Coppé JP, Patil CK, Hoeijmakers WA, Muñoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11:973–979PubMedCrossRefGoogle Scholar
  91. Ruiz M (2010) Lung cancer in HIV-infected patients: the experience of an urban clinic. J Int Assoc Physicians AIDS Care 9(4):214–217CrossRefGoogle Scholar
  92. Ruiz M, Cefalu C (2011) Characteristics of frail patients in a geriatric-HIV program: the experience of an urban academic center at one year follow-up. J Int Assoc Physicians AIDS Care 10(3):138–143CrossRefGoogle Scholar
  93. Sacktor N, Lyles RH, Skolasky R (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 56:257–260PubMedCrossRefGoogle Scholar
  94. Sacktor N, Skolasky RL, Cox C, Selnes O, Becker JT, Cohen B, Martin E, Miller EN (2010) Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus. J Neurovirol 16(5):335–341PubMedCrossRefGoogle Scholar
  95. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203:780–790PubMedCrossRefGoogle Scholar
  96. Sharma A, Flom PL, Weedon J, Klein RS (2010) Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 24(15):2337–2345PubMedGoogle Scholar
  97. Shiels MS, Pfeiffer RM, Engels EA (2010) Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 153(7):452–460PubMedGoogle Scholar
  98. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753–762PubMedCrossRefGoogle Scholar
  99. Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U, Hein G, Hüfner M (2003) Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 18(3):529–538PubMedCrossRefGoogle Scholar
  100. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI (2009) HIV infection and the risk of cancers with and without a known infectious cause. AIDS 23(17):2337–23345PubMedCrossRefGoogle Scholar
  101. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW (2005) Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 5:98PubMedCrossRefGoogle Scholar
  102. Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, DiPietro M, Ciuffreda D, Saracco A, Lazzarin A (2000) Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 30(6):962–965PubMedCrossRefGoogle Scholar
  103. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C (2010) Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55(3):316–322PubMedCrossRefGoogle Scholar
  104. Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, Tassandin C, Tambussi G, Grutzmeier S, Lopalco L, De Milito A (2005) Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 19:1947–1955PubMedCrossRefGoogle Scholar
  105. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH (2008) Endothelial function in human immunodeficiency virus-infected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152 s. J Am Coll Cardiol 52(7):569–576PubMedCrossRefGoogle Scholar
  106. Triant VA, Lee H, Hadigan C, Grinspoon SK (2007) Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92(7):2506–2512PubMedCrossRefGoogle Scholar
  107. Triant VA, Meigs JB, Grinspoon SK (2009) Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 51(3):268–273PubMedCrossRefGoogle Scholar
  108. Tsaknaridis L, Spencer L, Culbertson N, Hicks K, LaTocha D, Chou YK, Whitham RH, Bakke A, Jones RE, Offner H, Bourdette DN, Vandenbark AA (2003) Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 74:296–308PubMedCrossRefGoogle Scholar
  109. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N (2004) Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63(5):822–827PubMedCrossRefGoogle Scholar
  110. Valcour V, Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C (2008) Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol 14(5):362–367PubMedCrossRefGoogle Scholar
  111. Valcour VG, Shiramizu BT, Shikuma CM (2010) HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol 7:621–626CrossRefGoogle Scholar
  112. Valcour V, Sithinamsuwan P, Letendre S, Ances B (2011) Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 8(1):54–61PubMedCrossRefGoogle Scholar
  113. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F (2010) Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24:1527–1535PubMedCrossRefGoogle Scholar
  114. Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A (2003) Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS Suppl 1:S70–S76CrossRefGoogle Scholar
  115. Vivithanaporn P, Maingat F, Lin LT, Na H, Richardson CD, Agrawal B, Cohen EA, Jhamandas JH, Power C (2010) Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. PLoS One 5(9):e12856PubMedCrossRefGoogle Scholar
  116. Vogel M, Friedrich O, Lüchters G, Holleczek B, Wasmuth JC, Anadol E, Schwarze-Zander C, Nattermann J, Oldenburg J, Sauerbruch T, Rockstroh JK, Spengler U (2011) Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 16(3):101–107PubMedCrossRefGoogle Scholar
  117. Watters MR, Poff PW, Shiramizu BT, Holck PS, Fast KM, Shikuma CM, Valcour VG (2004) Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 62(8):1378–1383PubMedCrossRefGoogle Scholar
  118. Winston A, Duncombe C, Li PCK, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50:920–929PubMedCrossRefGoogle Scholar
  119. Wright E (2009) Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIVAIDS 4(5):447–452CrossRefGoogle Scholar
  120. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75(10):864–873PubMedCrossRefGoogle Scholar
  121. Ye Y, Zeng Y, Li X, Zhang S, Fang Q, Luo L, Qiu Z, Han Y, Li T (2010) HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr 53(2):276–278PubMedCrossRefGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2011

Authors and Affiliations

  • Ramona Bhatia
    • 1
  • Patrick Ryscavage
    • 2
  • Babafemi Taiwo
    • 1
  1. 1.Northwestern University Feinberg School of MedicineDivision of Infectious DiseasesChicagoUSA
  2. 2.Institute of Human VirologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations